Oncology Institute (TOI) Expected to Announce Earnings on Thursday

Oncology Institute (NASDAQ:TOI) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $155.28 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to analyst estimates of $142.10 million. On average, analysts expect Oncology Institute to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncology Institute Trading Up 1.1%

Oncology Institute stock traded up $0.06 during trading on Tuesday, hitting $5.19. The company had a trading volume of 1,263,820 shares, compared to its average volume of 1,941,710. Oncology Institute has a 1-year low of $2.32 and a 1-year high of $6.67. The company’s 50 day simple moving average is $5.19 and its 200-day simple moving average is $3.92. The stock has a market cap of $512.58 million, a price-to-earnings ratio of -14.02 and a beta of 0.39.

Insider Buying and Selling at Oncology Institute

In other news, insider Yale Podnos sold 23,451 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. The trade was a 8.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 33,500 shares of Oncology Institute stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $4.07 per share, for a total transaction of $136,345.00. Following the acquisition, the insider owned 10,567,858 shares of the company’s stock, valued at $43,011,182.06. This represents a 0.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 131,500 shares of company stock valued at $609,265 over the last three months. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oncology Institute

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new position in Oncology Institute in the fourth quarter valued at $31,000. Cetera Investment Advisers increased its holdings in shares of Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after acquiring an additional 4,545 shares during the last quarter. State of Wyoming acquired a new position in Oncology Institute in the second quarter valued at approximately $37,000. Prelude Capital Management LLC purchased a new position in Oncology Institute in the third quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets raised its holdings in Oncology Institute by 141.0% during the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares in the last quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TOI has been the subject of a number of research reports. Needham & Company LLC lifted their price objective on Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Lake Street Capital started coverage on shares of Oncology Institute in a research note on Monday, July 6th. They set a “buy” rating and a $10.00 price target on the stock. BTIG Research increased their price target on shares of Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research note on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.50.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.